Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: L04AA32

Apremilast Viatris(apremilast)

Arthritis, Psoriatic;Psoriasis;Behcet Syndrome

Marketing Authorisation Holder: Viatris Limited

INN: apremilast

Indication

Treatment of psoriatic arthritis, psoriasis, Behçet’s disease.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Apremilast Viatris — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.